CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Pneumobase.it

Search results for "Valsartan"

Diovan ( Valsartan ) received European Union ( EU ) approval for the treatment of heart attack survivors. Diovan is now indicated as a potentially life-saving therapy for the more than 750,000 peop ...


According to the VAST study, patients with moderate to severe hypertension treated with a combination of Diovan ( Valsartan; Tareg ) and the diuretic hydrochlorothiazide ( HCTZ ) (160/25) benefited fr ...


Studies have shown that low hemoglobin, which may result in anemia, is more common among patients with heart failure than it is among people in the general population. As many as 25 percent to 60 per ...


Combining Aliskiren ( Rasilez / Tekturna ) with Valsartan ( Diovan / Tareg ) at maximum recommended doses provides significantly greater reductions in blood pressure than does monotherapy with either ...


The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and imp ...


The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. Researc ...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart ...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New ...


The effect of LCZ696 on blood pressure was evaluated in patients with heart failure with preserved ejection fraction ( HFpEF ) in the PARAMOUNT ( Prospective comparison of ARNI with ARB on Management ...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared with Enalapril in patients with chroni ...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with Entresto ( Sacubitril / Valsartan ) tablets were readm ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published in European Heart Journal and the European Journal of Heart Failure, ...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit of Sacubitril / Valsartan therapy shown in the PARADIGM-HF ( ...